Citations

Mayo Clinic

Showing 10 of 108572 citations.

Pretreatment growth rate as a predictor of tumor control following Gamma Knife radiosurgery for sporadic vestibular schwannoma
Jacob, Jeffrey T. , Carlson, Matthew L. , Pollock, Bruce E. , Driscoll, Colin L. W., Link, Michael J. , Marston, Alexander P.

Journal of Neurosurgery | November 25, 2016 | Volume: 127 | Issue: 2 | Pages: 380-387

10.3171/2016.5.jns153013 | PMID 27885952 Get It

OBJECTIVEOver the last 30 years, stereotactic radiosurgery (SRS) has become an established noninvasive treatment alternative for small- to medium-sized vestibular schwannoma (VS). This study aims to further define long-term SRS tumor control in patients with documented pretreatment tumor growth for whom conservative observation failed.METHODSA prospective clinical database was queried, and patients with sporadic VS who elected initial observation and subsequently underwent SRS after documented tumor growth between 2004 and 2014 were identified. Posttreatment tumor growth or shrinkage was determined by a ≥ 2-mm increase or decrease in maximum linear dimension, respectively.RESULTSSixty-eight patients met study inclusion criteria. The median pre- and posttreatment observation periods were 16 and 43.5 months, respectively. The median dose to the tumor margin was 13 Gy (range 12–14 Gy), and the median maximum dose was 26 Gy (range 24–28 Gy). At the time of treatment, 59 tumors exhibited extracanalicular (EC) extension, and 9 were intracanalicular (IC). Of the 59 EC VSs, 50 (85%) remained stable or decreased in size following treatment, and 9 (15%) enlarged by > 2 mm. Among EC tumors, the median pretreatment tumor growth rate was 2.08 mm/year for tumors that decreased or were stable, compared with 3.26 mm/year for tumors that grew following SRS (p = 0.009). Patients who demonstrated a pretreatment growth rate of < 2.5 mm/year exhibited a 97% tumor control rate, compared with 69% for those demonstrating ≥ 2.5 mm/year of growth prior to SRS (p = 0.007). No other analyzed variables were found to predict tumor growth following SRS.CONCLUSIONSOverall, SRS administered using a marginal dose between 12–14 Gy is highly effective in treating VSs in which initial observation fails. Tumor control is achieved in 97% of VSs that exhibit slow (< 2.5 mm/year) pretreatment growth; however, SRS is less successful in treating tumors exhibiting rapid growth (≥ 2.5 mm/year).
Invited Commentary on “MR Enterography of Inflammatory Bowel Disease with Endoscopic Correlation”
Fidler, Jeff L. , Fidler, Jeff L.

RadioGraphics | November 25, 2016 | Volume: 37 | Issue: 1 | Pages: 132-135

10.1148/rg.2016160185 | PMID 27885892 Get It

Facial Nerve Meningioma: A Cause of Pediatric Facial Weakness
Deep, Nicholas L. , Gnagi, Sharon H. , Carpentieri, David , Adelson, P. David , Weisskopf, Peter A., Carpentieri, David

Otology & Neurotology | November 25, 2016 | Volume: 38 | Issue: 3 | Pages: e8-e12

10.1097/mao.0000000000001293 | PMID 27898606 Get It

Objective: To present an unusual case of a temporal bone meningioma with intrafascicular spread throughout the temporal facial nerve from cerebellopontine angle (CPA) to stylomastoid foramen. Patient: Four-year-old female with progressive facial weakness and normal hearing. Main Outcome Measure: Clinical, radiological, and histopathological findings of temporal bone meningiomas. Results: A patient presented with progressive facial weakness and normal hearing. Imaging demonstrated a mass within the left internal auditory canal radiologically consistent with a schwannoma. Asymmetric enlargement with enhancement of the left facial nerve from CPA to the stylomastoid foramen suggested facial schwannoma. At surgery, gross tumor was noted in the internal auditory canal, the fallopian canal seemed expanded and the facial nerve was enlarged and had an irregular contour. Resection of the facial nerve from the CPA to just proximal to its exit at the stylomastoid foramen was necessary to achieve negative margins. Cable grafting was performed. The histopathologic diagnosis was transitional meningioma with intraneural growth throughout the length of the resected facial nerve segment. Conclusion: Meningiomas involving the temporal bone are exceedingly rare. We report a rare case of a child presenting with progressive facial weakness due to a presumed facial schwannoma spreading along the facial nerve throughout its intratemporal course that at surgery was found to be an intrafascicular CN VII meningioma.
Cardiac responses to exercise distinguish postural orthostatic tachycardia syndrome variants
Pianosi, Paolo T. , Schroeder, Darrell R. , Fischer, Philip R. , Pianosi, P T , Schroeder, Darrell

Physiological Reports | November 24, 2016 | Volume: 4 | Issue: 22 | Pages: e13040

10.14814/phy2.13040 | PMID 27884959 Get It

Diffuse pulmonary extramedullary hematopoiesis in myelofibrosis diagnosed with technetium‐99m sulfur colloid bone marrow scintigraphy and single photon emission computerized tomography/CT
Yang, Ming , Roarke, Michael C., Roarke, Michael

American Journal of Hematology | November 24, 2016 | Volume: 92 | Issue: 3 | Pages: 323-324

10.1002/ajh.24616 | PMID 27883206 Get It

2‐Methoxyestradiol‐Mediated Induction of Frzb Contributes to Cell Death and Autophagy in MG63 Osteosarcoma Cells
Bravo, Dalibel , Shogren, Kristen L., Zuo, Dongqing , Wagner, Eric R. , Sarkar, Gobinda , Yaszemski, Michael J. , Maran, Avudaiappan , Wagner, Eric R

Journal of Cellular Biochemistry | November 24, 2016 | Volume: 118 | Issue: 6 | Pages: 1497-1504

10.1002/jcb.25809 | PMID 27883247 Get It

ABSTRACTOsteosarcoma is a bone tumor that mainly affects children and adolescents. Although its pathogenesis is still not fully understood, activation of Wnt signaling has been implicated in the development and metastasis of osteosarcoma. In this report, we have investigated the effect of the anti‐tumor compound, 2‐methoxyestradiol (2‐ME) on Wnt antagonist frizzled‐related protein b (Frzb), also known as secreted frizzled‐related protein (sFRP)3 in human osteosarcoma (MG63) cells. Our results show that 2‐ME treatment induces Frzb gene promoter activity, and increases Frzb mRNA and protein levels in osteosarcoma cells. In addition, 2‐ME treatment regulates downstream Wnt signaling, increasing the cytoplasmic levels of β‐catenin, and blocking β‐catenin‐mediated Wnt activation in osteosarcoma cells. 2‐ME‐mediated induction of Frzb protein expression is specific to osteosarcoma cells, as it does not affect Frzb expression in normal primary human osteoblasts. Furthermore, 2‐ME‐induced apoptosis and autophagy are blocked in osteosarcoma cells transfected with Frzb siRNAs. Taken together, these studies demonstrate that Frzb protein plays an important role in 2‐ME‐mediated anti‐tumor mechanisms in osteosarcoma cells. J. Cell. Biochem. 118: 1497–1504, 2017. © 2016 Wiley Periodicals, Inc.
3D tract‐specific local and global analysis of white matter integrity in Alzheimer's disease
Huang, Chao , Daianu, Madelaine, Jack, Clifford R. , Thompson, Paul M. , Initiative, Alzheimer's Disease Neuroimaging, Jin, Yan , Zhan, Liang , Dennis, Emily L. , Reid, Robert I. , Zhu, Hongtu , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Thompson, Paul M

Human Brain Mapping | November 24, 2016 | Volume: 38 | Issue: 3 | Pages: 1191-1207

10.1002/hbm.23448 | PMID 27883250 Get It

AbstractAlzheimer's disease (AD) is a chronic neurodegenerative disease characterized by progressive decline in memory and other aspects of cognitive function. Diffusion‐weighted imaging (DWI) offers a non‐invasive approach to delineate the effects of AD on white matter (WM) integrity. Previous studies calculated either some summary statistics over regions of interest (ROI analysis) or some statistics along mean skeleton lines (Tract Based Spatial Statistic [TBSS]), so they cannot quantify subtle local WM alterations along major tracts. Here, a comprehensive WM analysis framework to map disease effects on 3D tracts both locally and globally, based on a study of 200 subjects: 49 healthy elderly normal controls, 110 with mild cognitive impairment, and 41 AD patients has been presented. 18 major WM tracts were extracted with our automated clustering algorithm—autoMATE (automated Multi‐Atlas Tract Extraction); we then extracted multiple DWI‐derived parameters of WM integrity along the WM tracts across all subjects. A novel statistical functional analysis method—FADTTS (Functional Analysis for Diffusion Tensor Tract Statistics) was applied to quantify degenerative patterns along WM tracts across different stages of AD. Gradually increasing WM alterations were found in all tracts in successive stages of AD. Among all 18 WM tracts, the fornix was most adversely affected. Among all the parameters, mean diffusivity (MD) was the most sensitive to WM alterations in AD. This study provides a systematic workflow to examine WM integrity across automatically computed 3D tracts in AD and may be useful in studying other neurological and psychiatric disorders. Hum Brain Mapp 38:1191–1207, 2017. © 2016 Wiley Periodicals, Inc.
Faculty Opinions recommendation of The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
McGehee, Cordelia D. , Kaufmann, Scott H.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 24, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726861250.793525591 Get It

Nivolumab in the Treatment of Hodgkin Lymphoma
Ansell, Stephen M.

Clinical Cancer Research | November 24, 2016 | Volume: 23 | Issue: 7 | Pages: 1623-1626

10.1158/1078-0432.ccr-16-1387 | PMID 27881581 Get It

Abstract Despite an extensive immune infiltrate that is recruited to the tumor by malignant Reed–Sternberg cells in Hodgkin lymphoma, the antitumor immune response is ineffective and unable to eradicate the malignant cells. The ineffective immune response is in part due to PD-1 signaling that renders intratumoral immune cells anergic. Reed–Sternberg cells have been shown to upregulate expression of the PD-1 ligands, PD-L1 and PD-L2, due to either genetic alterations at chromosome 9p24.1 or Epstein–Barr virus infection, and these ligands suppress the function of PD-1+ intratumoral T cells. Blockade of PD-1 signaling has proven to be a highly successful therapeutic approach, and the use of the anti-PD-1 mAb nivolumab recently received accelerated approval by the FDA for patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous stem cell transplant and posttransplantation brentuximab vedotin. Initial clinical trials using nivolumab in this patient population resulted in high response rates that were durable. Adverse events associated with nivolumab included immune-mediated adverse reactions and infusion reactions, but these were well tolerated, allowing for continued nivolumab administration. Clinical trials are now in progress to test the use of nivolumab in combination with standard chemotherapy or with novel agents with a goal of improving the outcome of patients with Hodgkin lymphoma. Clin Cancer Res; 23(7); 1623–6. ©2016 AACR.
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
Shi, Qian , Foster, Nathan R. , Grothey, Axel, Nair, Suresh , Chan, Emily , Shields, Anthony F. , Goldberg, Richard M. , Kahlenberg, Morton S., Singh, Preet Paul , Gill, Sharlene , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R. , Shi, Qian

The Oncologist | November 24, 2016 | Volume: 21 | Issue: 12 | Pages: 1509-1521

10.1634/theoncologist.2016-0153 | PMID 27881709 Get It

AbstractBackground.Preclinical and epidemiological data suggest that metformin might have antineoplastic properties against colon cancer (CC). However, the effect of metformin use on patient survival in stage III CC after curative resection is unknown. The survival outcomes were comparable regardless of the duration of metformin use.Patients and Methods.Before randomization to FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) with or without cetuximab, 1,958 patients with stage III CC enrolled in the N0147 study completed a questionnaire with information on diabetes mellitus (DM) and metformin use. Cox models were used to assess the association between metformin use and disease-free survival (DFS), overall survival (OS), and the time to recurrence (TTR), adjusting for clinical and/or pathological factors.Results.Of the 1,958 patients, 1,691 (86%) reported no history of DM, 115 reported DM with metformin use (6%), and 152 reported DM without metformin use (8%). The adjuvant treatment arms were pooled, because metformin use showed homogeneous effects on outcomes across the two arms. Among the patients with DM (n = 267), DFS (adjusted hazard ratio [aHR], 0.90; 95% confidence interval [CI], 0.59–1.35; p = .60), OS (aHR, 0.99; 95% CI, 0.65–1.49; p = .95), and TTR (aHR, 0.87; 95% CI, 0.56–1.35; p = .53) were not different for the metformin users compared with the nonusers after adjusting for tumor and patient factors. The survival outcomes were comparable regardless of the duration of metformin use (&lt;1, 1–5, 6–10, ≥11 years) before randomization (ptrend = .64 for DFS, ptrend = .84 for OS, and ptrend = .87 for TTR). No interaction effects were observed between metformin use and KRAS, BRAF mutation status, tumor site, T/N stage, gender, or age.Conclusions.Patients with stage III CC undergoing adjuvant chemotherapy who used metformin before the diagnosis of CC experienced DFS, OS, and TTR similar to those for non-DM patients and DM patients without metformin use.